DOI: https://doi.org/10.24959/uekj.20.25

Analysis of the domestic pharmaceutical market of psychostimulants and nootropic drugs of N06BX group

B. S. Burlaka, I. F. Belenichev, N. M. Sincha, K. A. Sincha, Fadi Al Zedan

Abstract


Aim. To study the nomenclature of synthetic and herbal N06BX group, presented on the pharmaceutical market ofUkraine.

Results. According to the State Expert Center of the Ministry of Health of Ukraine, the pharmaceutical market of Ukraine presents 14 international non-proprietary names (INN) of drugs or 214 trade names of drugs, including forms of release registered as of the classification of ATC; December, 2019. The range of these drugs has been represented by drugs analogues, both synthetic and herbal. In total, according to the list of N06BX group, there are 29 countries producing drugs of this group.

Conclusions. The market of N06BX group inUkraine has been analyzed and it has been established that drugs of domestic production occupy 52.91 %, foreign – 39.68 %, joint ventures of Ukrainian producers with foreign – 7.41 %. The main market share in the general nomenclature of the N06BX group belongs to the following manufacturers: PJSC Farmak, LLC Pharmaceutical Company Zdorovya and PJSC Pharmaceutical Firm Darnytsia. Among foreign manufacturers, the leaders are – manufacturers fromLatvia,Poland andHungary. It should be noted that pharmaceutical market ofUkraine presents 5 joint ventures with foreign countries producing drugs of N06BX group. As active substances used: citicoline, vinpocetine, piracetam, phenibut, mebicar and herbal preparations of the Ginkgo Biloba group. Release forms: solutions for injections, drops for oral use, tablets, capsules. Taking into account the lack of registered dosage forms of n-phenyl-acetyl-L-prolylglycine on the domestic market, as well as the prospects of using a nasal dosage form for transporting the active substance directly into the brain, it is advisable to conduct further research.


Keywords


n-phenyl-acetyl-L-prolylglycine; nootropics; market analysis; cerebroprotectors

References


Gudasheva, T. A., Ostrovskaya, R. U., Seredenin, S. B. (2018). Novel Technologies for Dipeptide Drugs Design and their Implantation. Current pharmaceutical design, 24 (26), 3020-3027. doi: https://doi.org/10.2174/1381612824666181008105641

Savelieva, O. V., Shumova, H. S., Vladymyrova,I.M. (2015). ScitnceRise, 14 (4), 30–36. doi: https://doi.org/10.15587/2313-8416.2015.54873

Vostrikov, V. V. (2017). Obzory Po Klinicheskoi Farmakolohii i Lekarstvennoi Terapii, 15 (1), 14–25. doi: 10.17816/RCF15114-25

Suliman, N. A., Mat Taib, C. N., Mohd Moklas, M. A., Adenan, M. I., Hidayat Baharuldin, M. T., Basir, R. (2016) Establishing Natural Nootropics: Recent Molecular Enhancement Influenced by Natural Nootropic. Evidence-based complementary and alternative medicine,1-12. doi: https://doi.org/10.1155/2016/4391375

Belenichev,I.F. (2014). Neiroprotektsiia i neiroplastichnost. Kiyev: Poligraf plius, 512.

Kashyap, K., Shukla, R. (2019). Drug Delivery and Targeting to the Brain ThroughNasal Route: Mechanisms, Applications and Challenges. Curr Drug Deliv, 16 (10), 887-901. doi: https://doi.org/10.2174/1567201816666191029122740

Talih, F., Ajaltouni, J. (2015). Probable Nootropicinduced Psychiatric Adverse Effects: A Series of Four Cases. Innovations in clinical neuroscience, 12 (11-12), 21–25.

Winblad, B. (2005). Piracetam: A Review of Pharmacological Properties and Clinical Uses. CNS Drug Reviews, 11, 169-182. doi: https://doi.org/10.1111/j.1527-3458.2005.tb00268.x

Derzhavnyi reiestr likarskykh zasobiv Ukrainy. Available at: www.drlz.kiev.ua.

Abdulkarim, A. N., Bushuieva,I.V., Hladysheva, S. A. (2018). Aktualni Pytannia Farmatsevtychnoi i Medychnoi Nauky Ta Praktyky, 11 (3), 339–345. doi: 10.14739/2409-2932.2018.3.145256

Frati, P., Kyriakou, C.,Del Rio, A., Marinelli, E., Vergallo, G. M., Zaami, S., Busardò, F. P. (2015). Smart drugs and synthetic androgens for cognitive and physical enhancement: revolving doors of cosmetic neurology. Current neuropharmacology, 13 (1), 5–11. doi: https://doi.org/10.2174/1570159X13666141210221750

Kompendium. Lekarstvennyie preparatyi. Available at: http://сompendium.com.ua/


GOST Style Citations


1.   Gudasheva T. A., Ostrovskaya R. U., Seredenin S. B. Novel Technologies for Dipeptide Drugs Design and their Implantation. Current pharmaceutical design. 2018. Vol. 24 (26). P. 3020-3027. DOI: https://doi.org/10.2174/1381612824666181008105641 (Date of access: 23.06.2020).

 

2.   Савельєва О. В., Шумова Г. С., Владимирова І. М. Аналіз фармацевтичного ринку ноотропних засобів в Україні. ScitnceRise. 2015. № 14/4 (16). С. 30-36. DOI: https://doi.org/10.15587/2313-8416.2015.54873 (дата звернення: 23.06.2020).

 

3.   Востриков В. В. Место пирацетама в современной практической медицине. Обзоры по клинической фармакологии и лекарственной терапии. 2017. № 15 (1). С. 14-25. DOI: https://doi.org/10.17816/RCF15114-25 (дата звернення: 23.06.2020).

 

4.   Establishing Natural Nootropics: Recent Molecular Enhancement Influenced by Natural Nootropic / N. A. Suliman et al. Evidence-based complementary and alternative medicine : eCAM. 2016. P. 1-12. DOI: https://doi.org/10.1155/2016/4391375 (Date of access: 23.06.2020).

 

5.   Нейропротекция и нейропластичность : монография / И. Ф Беленичев и др. Киев : Полиграф плюс, 2014. 512 с.

 

6.   Kashyap K., Shukla R. Drug Delivery and Targeting to the Brain Through Nasal Route: Mechanisms, Applications and Challenges. Curr Drug Deliv. 2019. Vol. 16 (10). P. 887-901. DOI: https://doi.org/10.2174/1567201816666191029122740 (Date of access: 23.06.2020).

 

7.   Talih F., Ajaltouni J. Probable Nootropicinduced Psychiatric Adverse Effects: A Series of Four Cases. Innovations in clinical neuroscience. 2015. Vol. 12 (11-12). P. 21–25.

 

8.   Winblad B. Piracetam: A Review of Pharmacological Properties and Clinical Uses. CNS Drug Reviews. 2005. Vol. 11. P. 169-182. DOI: https://doi.org/10.1111/j.1527-3458.2005.tb00268.x (Date of access: 23.06.2020).

 

9.   Державний реєстр лікарських засобів України. URL: www.drlz.kiev.ua (дата звернення: 23.06.2020).

 

10. Ал Нукарі Абдулкарім, Бушуєва І. В., Гладишева С. А. Позиціювання ноотропних лікарських засобів на національному ринку. Актуальні питання фармацевтичної і медичної науки та практики. 2018. Т. 11, № 3. С. 339-345. DOI: https://doi.org/10.14739/2409-2932.2018.3.145256 (дата звернення: 23.06.2020).

 

11. Smart drugs and synthetic androgens for cognitive and physical enhancement: revolving doors of cosmetic neurology / P. Frati et a. Current neuropharmacology. 2005. Vol. 13 (1). P. 5–11. DOI: https://doi.org/10.2174/1570159X13666141210221750 (Date of access: 23.06.2020).

 

12. Компендиум. Лекарственные препараты. URL: http://сompendium.com.ua/ (дата звернення: 23.06.2020).





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Manag. econ. qual. assur. pharm.

ISSN 2519-8807 (Online), ISSN 2311-1127 (Print)